Thoma Bravo acquires kneat.com
Structured as an all-cash public-to-private, the offer gives shareholders C$6.50, 40% above the unaffected Toronto trading price.
Takeaways
- Kneat is a digital validation and quality process automation platform for life sciences.
- Thoma Bravo is acquiring Kneat.
- The target serves life sciences across Ireland.
Under a definitive arrangement agreement, Kneat, an Ireland-based digital validation and quality process automation software provider for life sciences customers, will move into Thoma Bravo ownership.
The platform digitizes validation data for integrity and traceability in regulated environments, supporting compliance workflows across life sciences manufacturing and quality processes.
The equity value is approximately C$650 million on a fully diluted, in-the-money treasury-stock-method basis, inclusive of any rollover shares.
“In today’s increasingly complex regulatory environment, more customers are looking to Kneat to provide them with greater control, efficiency, and real-time visibility across mission-critical compliance workflows,” said Adam Solomon, a Partner at Thoma Bravo.
Upon completion, Kneat will become a privately held company; the arrangement has unanimous board approval, remains subject to shareholder and customary approvals, and has no financing condition.
Thoma Bravo has sufficient resources to fund the purchase.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.